Ixico struggles with higher costs
Clinical trial services provider Ixico (IXI:AIM) is under pressure as it posts a significantly widened full year operating loss of £2.9m due to higher costs. Shares in Ixico have fallen 12% to 33p.The company supports clinical...
20 December 2016
